Concurrent intrathecal nivolumab and targeted therapy in a patient with melanoma-associated leptomeningeal disease
- PMID: 39264713
- DOI: 10.1111/jdv.20336
Concurrent intrathecal nivolumab and targeted therapy in a patient with melanoma-associated leptomeningeal disease
References
REFERENCES
-
- Wolchok JD, Chiarion‐Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long‐term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone versus Ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127–137.
-
- Tawbi HA, Forsyth PA, Hodi FS, Algazi AL, Hamid O, Lao CD, et al. Long‐term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open‐label, multicentre, phase 2 study. Lancet Oncol. 2021;22(12):1692–1704.
-
- Ferguson SD, Bindal S, Bassett RL, Haydu LE, McCutcheon IE, Heimberger AB, et al. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neuro‐Oncol. 2019;142:499–509.
-
- Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023;29:898–905.
-
- Glitza IC, Rohlfs M, Guha‐Thakurta N, Basset RL, Bernatchez C, Diab A, et al. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin‐2. ESMO Open. 2018;3(1):e000283.
Publication types
LinkOut - more resources
Full Text Sources
